A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease.

[1]  M. Boeckh,et al.  Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  D. Zahrieh,et al.  Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. , 2004, Blood.

[3]  J. Ritz,et al.  Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.

[4]  B. Andersson,et al.  Tumor necrosis factor-blockade for the treatment of acute GVHD , 2004 .

[5]  R. Krance,et al.  Prompt versus preemptive intervention for EBV lymphoproliferative disease. , 2004, Blood.

[6]  B. van der Holt,et al.  Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. , 2002, Blood.

[7]  Paul Martin,et al.  A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. , 2002, Blood.

[8]  M. Remberger,et al.  Treatment of severe acute graft‐versus‐host disease with anti‐thymocyte globulin , 2001, Clinical transplantation.

[9]  R. Vij,et al.  Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin , 2001, Bone Marrow Transplantation.

[10]  S. Durrant,et al.  Combination therapy with tacrolimus and anti‐thymocyte globulin for the treatment of steroid‐resistant acute graft‐versus‐host disease developing during cyclosporine prophylaxis , 2001, British journal of haematology.

[11]  T. Gooley,et al.  Non-Fc Receptor-Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated Human T Cells1 , 2000, The Journal of Immunology.

[12]  V. Emery,et al.  High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients , 2000, British journal of haematology.

[13]  C. Currie,et al.  Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. , 2000, Journal of hematotherapy & stem cell research.

[14]  E. Jaffe,et al.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. , 1999, Blood.

[15]  C. Anasetti,et al.  HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. , 1999, Transplantation.

[16]  J Wagner,et al.  B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome , 1999, Bone Marrow Transplantation.

[17]  S. Nantel,et al.  Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience , 1998 .

[18]  C. Anasetti,et al.  Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. , 1997, Journal of immunology.

[19]  H. Deeg,et al.  Evaluation of a CD5-specific immunotoxin for treatment of acute graft- versus-host disease after allogeneic marrow transplantation , 1996 .

[20]  M. Folstein,et al.  Population-based norms for the Mini-Mental State Examination by age and educational level. , 1993, JAMA.

[21]  P. Ljungman,et al.  Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. , 1990, The Journal of infectious diseases.

[22]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[23]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[24]  K. Cleary,et al.  Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. , 2000, Blood.